Precef product monograph. Syracuse, Bristol Laboratories, September 1984: 14.
2.
PfefferMGaverRCVan HarkenDR. Human pharmacokinetics of a new broad-spectrum parenteral cephalosporin antibiotic, ceforanide. J Pharm Sci1980; 69: 398–402.
3.
SmythRDPfefferMGlickAVan HarkenDRHottendorfGH. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob Agents Chemother1979; 16: 615–21.
4.
LeeFHPfefferMVan HarkenDRSmythRDHottendorfGH. Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans. Antimicrob Agents Chemother1980; 17: 188–92.
5.
ThruppLDMillerRDWelchWD. Ceforanide dosage in the puerperium. Curr Ther Res1983; 34: 130–5.
6.
Ceforanide (Precef).Med Lett Drugs Ther1984; 26: 91–2.
7.
DudleyMNNightingaleCHQuintilianiRTiltonRC. In vitro activity of cefonicid, ceforanide, and cefazolin against Staphylococcus aureus and Staphylococcus epidermidis and the effect of human serum (letter). J Infect Dis1983; 148: 178.
8.
RappRPBlueD. The role of the extended half-life second-generation cephalosporins in surgical prophylaxis. Drug Intell Clin Pharm1985; 19: 214–6.
